p16表达缺失是恶性脑膜瘤中CDKN2A纯合缺失的敏感标志物。 - Suppr

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.

作者信息

Tang Vivian, Lu Rufei, Mirchia Kanish, Van Ziffle Jessica, Devine Patrick, Lee Julieann, Phillips Joanna J, Perry Arie, Raleigh David R, Lucas Calixto-Hope G, Solomon David A

机构信息

Department of Pathology, University of California San Francisco, 513 Parnassus Ave, Health Sciences West 451, San Francisco, CA, 94143, USA.

Clinical Cancer Genomics Laboratory, University of California San Francisco, San Francisco, CA, USA.

出版信息

Acta Neuropathol. 2023 Apr;145(4):497-500. doi: 10.1007/s00401-023-02544-6. Epub 2023 Feb 1.

DOI:10.1007/s00401-023-02544-6

PMID:36723772

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10020299/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1dca/10020299/155f883b1b1f/401_2023_2544_Fig1_HTML.jpg

相似文献

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.

Acta Neuropathol. 2023 Apr;145(4):497-500. doi: 10.1007/s00401-023-02544-6. Epub 2023 Feb 1.

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

Increased mRNA expression of CDKN2A is a transcriptomic marker of clinically aggressive meningiomas.

Acta Neuropathol. 2023 Jul;146(1):145-162. doi: 10.1007/s00401-023-02571-3. Epub 2023 Apr 24.

[Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].

Zhonghua Bing Li Xue Za Zhi. 2024 May 8;53(5):439-445. doi: 10.3760/cma.j.cn112151-20230815-00069.

Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Am J Pathol. 2001 Aug;159(2):661-9. doi: 10.1016/S0002-9440(10)61737-3.

p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.

Am J Surg Pathol. 2024 Jan 1;48(1):46-53. doi: 10.1097/PAS.0000000000002148. Epub 2023 Nov 10.

Correlation of MTAP Immunohistochemistry With CDKN2A Status Assessed by Fluorescence In Situ Hybridization and Clinicopathological Features in CNS WHO Grade 2 and 3 Meningiomas: A Single Center Cohort Study.

J Neuropathol Exp Neurol. 2022 Jan 29;81(2):117-126. doi: 10.1093/jnen/nlab127.

Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.

J Neurooncol. 2001 Dec;55(3):149-58. doi: 10.1023/a:1013863630293.

Analysis of CDKN2A gene alterations in recurrent and non-recurrent meningioma.

J Neurooncol. 2019 Dec;145(3):449-459. doi: 10.1007/s11060-019-03333-6. Epub 2019 Nov 15.

P16 immunohistochemistry is a sensitive and specific surrogate marker for CDKN2A homozygous deletion in gliomas.

Acta Neuropathol Commun. 2023 May 3;11(1):73. doi: 10.1186/s40478-023-01573-2.

引用本文的文献

EZH2 overexpression is associated with aggressive behavior and promotes cell proliferation in CNS WHO grade 3 meningiomas.

Neurooncol Adv. 2025 Jun 5;7(1):vdaf112. doi: 10.1093/noajnl/vdaf112. eCollection 2025 Jan-Dec.

Pitfalls in the evaluation of CDKN2A copy number status in meningioma.

J Neurooncol. 2025 Apr 14. doi: 10.1007/s11060-025-05029-6.

Deciphering the Differences Between Epstein-Barr Virus-Associated and Negative Gastric Cancer in the Prospect of CDKN2A Genomic Alterations and Lymphoid Infiltration.

Cancer Med. 2025 Jan;14(2):e70409. doi: 10.1002/cam4.70409.

MTAP and p16 IHC as Markers for CDKN2A/B Loss in Meningiomas.

Cancers (Basel). 2024 Sep 27;16(19):3299. doi: 10.3390/cancers16193299.

cIMPACT-NOW update 8: Clarifications on molecular risk parameters and recommendations for WHO grading of meningiomas.

Neuro Oncol. 2025 Feb 10;27(2):319-330. doi: 10.1093/neuonc/noae170.

Evaluation of prognostic biomarkers in meningiomas and their clinical implications in settings with limited resources.

Neurooncol Pract. 2024 Apr 9;11(4):464-474. doi: 10.1093/nop/npae027. eCollection 2024 Aug.

Paired Primary and Recurrent Rhabdoid Meningiomas: Cytogenetic Alterations, Gene Expression Profile and Patient Outcome.

Biology (Basel). 2024 May 16;13(5):350. doi: 10.3390/biology13050350.

Spatial genomic, biochemical and cellular mechanisms underlying meningioma heterogeneity and evolution.

Nat Genet. 2024 Jun;56(6):1121-1133. doi: 10.1038/s41588-024-01747-1. Epub 2024 May 17.

Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting status.

Neurooncol Adv. 2024 Jan 8;6(1):vdae002. doi: 10.1093/noajnl/vdae002. eCollection 2024 Jan-Dec.

Oncogene-induced senescence in meningiomas-an immunohistochemical study.

J Neurooncol. 2024 Jan;166(1):143-153. doi: 10.1007/s11060-023-04532-y. Epub 2023 Dec 20.

本文引用的文献

CDK 4/6 inhibitors for the treatment of meningioma.

Front Oncol. 2022 Jul 22;12:931371. doi: 10.3389/fonc.2022.931371. eCollection 2022.

Intratumor and informatic heterogeneity influence meningioma molecular classification.

Acta Neuropathol. 2022 Sep;144(3):579-583. doi: 10.1007/s00401-022-02455-y. Epub 2022 Jun 27.

Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities.

Nat Genet. 2022 May;54(5):649-659. doi: 10.1038/s41588-022-01061-8. Epub 2022 May 9.

J Neuropathol Exp Neurol. 2022 Jan 29;81(2):117-126. doi: 10.1093/jnen/nlab127.

A molecularly integrated grade for meningioma.

Neuro Oncol. 2022 May 4;24(5):796-808. doi: 10.1093/neuonc/noab213.

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.

Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.

Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma.

Nat Commun. 2020 Sep 23;11(1):4803. doi: 10.1038/s41467-020-18582-7.

CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.

Acta Neuropathol. 2020 Sep;140(3):409-413. doi: 10.1007/s00401-020-02188-w. Epub 2020 Jul 8.

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma.

Acta Neuropathol. 2019 Aug;138(2):295-308. doi: 10.1007/s00401-019-02008-w. Epub 2019 May 8.

Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.

Neuro Oncol. 2017 May 1;19(5):699-709. doi: 10.1093/neuonc/now254.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献